D unaltered monoclonal antibodies (MoAbs) have had limited success in cancer treatment (reviewed in reference I). The limited potency of these MoAbs was due to a variety of problems, primarily the inability or decreased ability of effector cells to eliminate MoAb-coated tumor cells. One promising, but as yet unproven, method to enhance MoAb efficacy is to use them to "focus" effector cells that have been qualitatively or quantitatively augmented by recombinant cytokines.
The process of determining whether a particular antibody can mediate antibody-dependent cellular cytotoxicity (ADCC) and if so, which cytokine is most able to augment the reaction, is a complex one that is influenced by each component of the reaction: the MoAb, the type of effector cell, and the tumor target. For example, although IgG2a and IgG3 murine MoAbs are thought to be the best mediators of ADCC with human effectors, there is no a priori method to determine this based on isotype alone, and not all MoAbs of these isotypes can participate in ADCC.2s3 Many types of leukocytes (eg, monocytes, large granular lymphocytes, granulocytes) can mediate ADCC, and depending on the subset being examined, a particular cytokine may have differential effects on their functions in tumor lysis. Most information on ADCC has been obtained using heterologous antisera and clinically irrelevant targets, such as chicken red blood cells (RBC). The information obtained with MoAbs that are therapeutic candidates has been confined largely to solid tumor targets with almost no information on B-cell malignancies. In fact, one study using IgG2a and IgG3 anti-idiotype MoAbs reported that they were unable to mediate ADCC against relevant lymphoma targets3 Granulocytes can mediate ADCC. 4 They are by far the numerically largest leukocyte subpopulation (up to IO-fold more than peripheral blood mononuclear cells [PBMC] ),' and with the advent of colony stimulating factors, they are among the most manipulable.(' Yet, granulocytes have been largely ignored as an effector cell in ADCC.
Lym-1 is an IgG2a MoAb that reacts with many B-cell malignancies. It binds to variant class I1 (HLA-DR family) molecules, has restricted reactivity with normal tissues, does not modulate, and the Lym-l antigen is not shed from the cell surface.' Because of these attractive properties, unconjugated Lym-1 has been used in Phase I trials of refractory B-cell tumors. Similar to the MoAb therapies mentioned previously, it produced only minor tumor
In an effort to improve the clinical utility of Lym-I, we have studied the effects of recombinant cytokines on Lym-lmediated ADCC. Previously, we demonstrated a marked enhancement of PBMC-mediated Lym-1 ADCC by interleukin-2 (IL-2)." In this study, we characterized the effects of IFN-y on granulocyte-mediated Lym-1 ADCC.
MATERIALS AND METHODS
Tumor cell lines and culture conditions. The human Burkitt lymphoma cell lines (Raji, Jijoye, EB3, Namalwa, and Daudi) and the erythroleukemia cell line K562 were obtained from the American Type Culture Collection (ATCC; Rockville, MD). The 8866, Epstein-Barr virus (EBV)-transformed, B lymphoblastoid cell line was obtained from R. Levy, Stanford University Medical Center, Stanford, CA." I937 is a class 11-positive subline of the U937 histiocytic non-Hodgkin's lymphoma cell line and was obtained from 0. Finn, Duke University Medical Center, Durham, NC."~'* CLL-3 is an EBV-transformed, malignant B cell derived from a patient with For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From chronic lymphocytic leukemia (CLL) and was obtained from T. Han, Roswell Park Cancer Institute. CLL-3 retains many of the phenotypic and cytogenetic characteristics of the original tumor cell.13 All cell lines were phenotyped with Lym-1 just before the assay. The intensity of Lym-1 antigen expression was determined by indirect immunofluorescence on a flow cytometer as described." Cell lines were cultured in complete medium (CM) consisting of RPMI 1640 medium, 10% heat-inactivated (56OC for 45 minutes) fetal calf serum, L-glutamine (2 mmol/L), nonessential amino acids (0.2 mmol/L), and HEPES buffer (0.02 mol/L) without antibiotics (GIBCO, Grand Island, NY). All cells were incubated at 37OC in a humidified 7.5% CO,, 95% air environment. Cell viability was determined by trypan blue exclusion and was usually greater than 95%.
Lym-1 was originally described by Epstein et a1; and was provided by F. Durr, Lederle Laboratory (Pearl River, NY). L203 (IgGl) and L243 (IgG2a) react with the same determinant on nonpolymorphic class I1 molecules." L227 (IgG1) reacts with a determinant common to HLA-DR, -DP, and -DQ." All MoAbs were greater than 90% pure as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). UPC-10 (IgG2a; Sigma, St Louis, MO) is a murine myeloma MoAb that was used as a negative control. MoAbs were filter-sterilized with 0.2 pm filters and stored at -2OOC. For immunofluorescence assays, granulocyte IgG Fc receptors were detected by MoAbs 32.2 (anti-CD64), IV.3 (anti-CD32), and 3G8 (anti-CD16). These MoAbs were purchased from Medarex (West Lebanon, NH) as purified (greater than 95%) immunoglobulin. Fluorescein-isothiocyanate (F1TC)-conjugated, Staphylococcus aureus Protein A (SPA) (Sigma) was used to determine whether SpA could bind to Lym-1 on the surface of Raji cells by an indirect immunofluorescence assay on the flow cytometer. Various amounts of FITC-SpA were added to Lym-lkoated Raji cells to determine the saturating concentration. Unconjugated SPA (Sigma) (4 x saturating concentration) was used in ADCC assays to determine whether SpA binding to Lym-1 could block Fc-Fc receptor interactions.
IFN-y was purchased from Collaborative Research Incorporated (Bedford, MA). Activity was determined by inhibition of encephalomyocarditis (EMC) virus propagation in WISH amnion cells. The IFN-y is greater than 98% pure by SDS-PAGE, has 2.9 x IO' U/mg protein, 0.069 endotoxin units/5 x IO5 U, and its amino acid composition correlates greater than 99% with native human IFN-y. Recombinant human IFN-a was obtained from Hoffmann-La Roche, Inc (Nutley, NJ), and had a specific activity of 2 x 10' U/mg protein. Recombinant human interleukin-2 (IL-2) was obtained from Hoffmann-La Roche, had a specific activity of 1.5 x IO' U/mg protein, and is greater than 95% pure.
Human eflector cells. After informed consent, venous blood was obtained by venipuncture from normal volunteers. The blood was collected into sterile tubes containing preservative-free heparin. Briefly, blood was layered onto neutrophil isolation medium (NIM; Los Alamos Diagnostics, LOS Alamos, NM). Separation and isolation of PBMC and granulocytes was done by differential gradient centrifugation at 400 g for 30 minutes at room temperature. The upper buffy coat consisted of PBMC and the lower, granulocytes. After isolation, the cells were washed twice and resuspended in CM. Viability was always greater than 95%. Purity was confirmed by microscopic inspection of Wright's-stained cytospin preparations, surface phenotype as estimated by immunofluorescence on a flow cytometer and by an Ortho Diagnostics ES/T 8000 Analyzer. As determined by the Ortho analyzer, the PBMC contained (st + SD): 83% + 6.5% lymphocytes, 10% * 5.6% monocytes, and 7% + 2.4% granulocytes. The granulocytes were 96% f 1.7% granulocytes and MoAbs and other reagents.
Recombinant human cytokines.
4% f 1.5% mononuclear cells (n = 8). The major non-nucleated cell contaminants in the PBMC were platelets; in the granulocytes, they were RBC.
Labeling was done by adding 100 pCi of 51Cr (specific activity, 250 to 500 mCi/mg chromium, Amersham Corporation, Arlington Heights, IL) to target cells in CM. After a 1-hour incubation at 37OC, the cells were washed twice in large volumes of RPMI 1640 and resuspended in CM. Labeled target cells
(1 x IO4) and effector cells at the desired effector:target (ET) ratios were plated into round-bottom microtiter trays (Corning 2585; Corning Glass Works, Corning, NY), with or without cytokines and MoAbs that had been diluted in CM. After approximately 20 hours of incubation at 37OC, tumor cell lysis was measured by determining the amount of 51Cr released by absorption of cultured supernatant into harvesting frame filters (Skatron Corp, Sterling, VA) followed by counting in a gamma counter (Beckman Model 5500b). The percent specific lysis was determined by the following equation: (E -S/M -S) x 100, where E is the average of triplicate sample counts per minute for experimental, S is the spontaneous release, and M is the maximal release for wells containing only target cells that were treated with 1% Triton X-100 detergent. Lytic units (LU) were derived from the cytotoxicity curves generated by a range of E:T ratios and were calculated by a modification of the linear regression line of best fit, as described by Pross et aI.l4 In the system, 1 LU is defined as the number of cells required to lyse 33% of the targets and is expressed per lo7 effector cells, so that the value increases with increasing lytic activity. The viability of granulocytes at the end of the ADCC assay was between 95% and 100%. and they were metabolically active (as determined by reduction of the tetrazolium salt MTT, as described"). In addition, cytoplasmic contents of lysed granulocytes did not cause 5'Cr release; thus, target cell killing was specific and not due to release of intracellular contents from dead or dying cells (data not shown).
Cytotoxicity assay.

RESULTS
Untreated granulocytes or PBMC had minimal to no lytic activity against the relatively natural killer (NK)-resistant Raji cell line (Fig 1) . The addition of IFN-y slightly enhanced PBMC nonantibody-mediated lysis, but had no effect on granulocytes. The addition of Lym-1 markedly enhanced tumor lysis by PBMC at most E:T ratios and, in the experiment shown in Fig 1, co-culture with IFN-y had no effect on PBMC-mediated Lym-1 ADCC. However, the effect of IFN-7 on PBMC-mediated ADCC was variable, since there was no effect in only a minor percentage of experiments. In most cases IFN--/ enhanced PBMCmediated Lym-1 A D C C (eg, see Figs To determine the effect of Lym-1 concentration on ADCC, dose-response experiments with a fixed amount of IFN-y (100 U/mL) were done (Fig 2) . Without cytokines, the optimal Lym-1 concentration for PBMC was approximately 10 pg/mL. In this particular experiment, IFN-y had no appreciable effect on PBMC ADCC above that seen with Lym-1 alone (Fig 2A) . As mentioned previously, IFN-y did augment PBMC-mediated Lym-1 ADCC in most individuals. Untreated granulocytes, in contrast, showed little to no Lym-1 ADCC even in the presence of 10 pg/mL of Lym-1 (Fig 2B) . IFN-y greatly enhanced granulocyte tumor cell lysis even at Lym-1 concentrations as low as 0.46 pg/mL. On the other hand, IL-2 augmented PBMC-mediated Lym-1 ADCC" but had no effect on granuloycte-mediated Lym-1 ADCC (data not shown). The importance of measuring tumor lysis at the highest E:T ratio ( 
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as by lytic units (solid bars) is emphasized in Fig 2. While IFN-.I augmented granulocyte tumor lysis at all Lym-1 concentrations, there was only a 2-to 2.5-fold increase in percent cytotoxicity from the lowest to the highest Lym-1 concentration used, whereas LU increased at least 10-fold. This underscores the finding (shown in Fig 1) that the effect of IFN-y was most evident a t lower granulocyte numbers.
To determine the optimal amount of IFN-y in granulocytemediated Lym-1 ADCC, concentrations ranging from 0.1 to 1000 U/mL were examined in the presence of a constant Lym-1 concentration (10 pg/mL) ( Table 1) . As noted by others,16," there is great variation in the degree of tumor lysis attained in different subjects. We have previously noted this in IL-2-enhanced PBMC-mediated Lym-1 ADCC." Despite intersubject variability, several general findings can be discerned from Table 1 : IFN-y consistently enhanced granulocyte-mediated Lym-1 ADCC at concentrations as low as 10 U/mL; the optimal concentration of IFN-y was approximately 100 U/mL; concentrations of IFN-y lower than 0.1 U/mL had no effect, while concentrations greater than 5,000 U/mL gave results similar to 1,000 U/mL (data not shown). Granulocytes without Lym-1 and IFN-y were unable to lyse tumor cells (Fig 1) . Granuloyctes from one individual (experiment 3), failed to consistently lyse tumor targets at E:T ratios of 40:l and lower, so E:T ratios of 80:l and lower were used.
Next, PBMC and granulocytes were compared to determine the degree of intersubject variability under optimal Lym-1 and IFN-y concentrations (10 pg/mL and 100 U/mL, respectively) ( Table 2 ). As before, PBMC alone had virtually no effect. The addition of IFN-y enhanced PBMCmediated tumor lysis in most individuals (as gauged by percent cytotoxicity at a 40:l E:T ratio), although not enough to generate increases in LU activity. PBMC were effective mediators of Lym-1 ADCC, and IFN-y boosted this activity in four of five subjects 14% to 136%. Granulocytes (with or without IFN-y) had no intrinsic tumor lytic ability. For - (2) - ( Four MoAbs were compared with Lym-1 to determine the role of isotype and specificity in granulocyte ADCC (Table  3) . UPC-10, an irrelevant yet isotype-matched control, was unable to elicit ADCC. Three distinct anti-class I1 MoAbs (L243, L203, L227), which reacted with Raji cells (as determined by fluorescence on a flow cytometer), were all able to mediate ADCC in the absence of IFN-7. IFN-y increased these reactions 13% to 54%, with the IgG2a MoAb (L243) showing the greatest increase. Lym-1 ADCC was enhanced by an average of 200% by IFN-y. These results are in contrast with those obtained with PBMC, where IgGl anti-class I1 MoAbs were unable to mediate ADCC even in the presence of IL-2."
To confirm that granulocyte-mediated tumor lysis and its augmentation by IFN-7 were due to interactions between Fc receptor (FcR)-bearing granulocytes and the Fc portion of Lym-1, the effect of SpA was examined (Fig 3) . SPA binds avidly to Lym-1, and fluoresceinated SpA was able to detect surface-bound Lym-1 on Raji cells as measured by flow cytometry (data not shown). In the absence of IFN-7, SpA completely inhibited both PBMC and granulocyte-mediated ADCC. IFN-7 augmentation of PBMC and granulocyte ADCC was inhibited 95% to 100%. It was unlikely that SpA was affecting either target cells or effectors, since non-ADCC lysis of Raji cells by PBMC was unaffected." These experiments suggested that the effect of IF"-y on granulocyte-mediated Lym-1 ADCC involved an Fc-FcR mecha- (Fig 4) . As reported by others using PBMC, IFN-a was able to enhance ADCC and non-ADCC tumor lysis." In these experiments, IFN-y had a similar effect on PBMC. In contrast, IFN-a had no (100 U/mL) or only a modest (1,000 U/mL) effect on granulocytemediated ADCC, especially when compared with IFN-y.
Granulocytes were primed with IFN-7 for 24 hours and washed extensively and their tumor lytic ability was compared with unprimed granulocytes (Fig 5) . This was done to determine whether IFN-y had to be continuously present during ADCC and to explore the specificity of the effect of IFN-7 on granulocytes. The ADCC of unprimed granulocytes was weak, despite the addition of 100 U/mL of IFN-y for the duration of the assay (Fig 5) . In contrast to fresh granulocytes, cultured granulocytes were less able to mediate ADCC, even in the presence of IFN-7. This effect was not due to decreased viability, since these granulocytes were greater than 95% viable. Priming with either 100 or 1,000 U/mL of INF-y greatly increased the granulocyte's ability to mediate ADCC. Further IFN-y exposure of primed granulocytes resulted in only a modest increase in tumor lysis. These latter two experiments showed the specificity of the effect of IFN-7 on granulocytes, showed that IFN-7 did not have to be present continuously during Lym-1 ADCC, and confirmed that IFN-7 was not altering the tumor targets. Throughout all of the previous experiments, the Lym-1
antigen-positive Burkitt lymphoma cell line Raji was used as a target. To determine the general applicability of these findings, eight cell lines were examined and compared with Raji (Fig 6) . These cells represent a continuum of Lym Expression of surface markers shown in column two was estimated by indirect immunofluorescence on the flow cytometer." Results are expressed as the percent positive cellslmean fluorescence intensity on a log scale. If the percent of cells staining positively was less than 5%. the mean fluorescence is not shown and is indicated by a dash. Control indicates cells stained with normal mouse immunoglobulin. For each marker, 2,000 to 4,000 granulocytes were analyzed. Experiments represent granulocytes from three different subjects that were incubated for 2 0 hours in CM alone ( -) or in CM containing 100 U/mL of IFN-7 (+). 1937) (Fig 6A) . For the cell lines that had minimal or no Lym-1 antigen expression (8866, Namalwa, Daudi, K562, EB3), NK or NK-like activity accounted for most or all tumor lysis, and Lym-1 ADCC did not consistently or appreciably augment cytotoxicity by PMBC. For granulocytes, there was no native cytotoxic activity against any tumor cell line. Granulocytes mediated weak Lym-1 ADCC against Raji and I937 targets but not against the CLL-3 cell. IFN-7 enhanced (Raji, 1937) or induced (CLL-3) Lym-1 ADCC against these three targets (Fig 6B) . Thus, several Lym-1 antigen-positive tumor targets of diverse origin and lineage can De lysed by granulocytes in Lym-1 ADCC. These results confirmed that intensity of expression of the target antigen is an important variable in ADCC. Similar findings have been reported in a different system.*
DISCUSSION
The major finding of this study is that IFN-y is able to augment or induce granulocyte-mediated, Lym-ldependent cytotoxicity against different tumor targets. Many investigators have shown that unstimulated granulocytes can readily lyse antibody-coated target^.^.^'.^^ However, these studies are not directly applicable to MoAb treatment of cancer patients, since they used polyclonal antisera reactive with irrelevant targets (eg, RBC or murine cells). In this study, untreated granulocytes had only weak or no activity in ADCC with the Lym-1 MoAb.
Recombinant IFN--, has been reported to stimulate MoAbmediated monocyte/macrophage and PBMC ADCC23324 but to inhibit ADCC mediated by large granular lymphocytes against melanoma targets.17 In most subjects, there was an augmentation of PBMC-mediated Lym-1 ADCC by IFN-7. The subjects that showed no increase with IFN--, generally had high levels of PBMC-mediated Lym-1 ADCC and may have already been a t maximal lysis (for example, see Table 2 , subject J.J.).
Recombinant IFN--, has been reported to augment granulocyte ADCC elicited by polyclonal antisera against chicken RBC'8.25.26 or murine targetsI9 and was most effective at suboptimal concentrations of antibody." Similar results have been reported with IFN-aZ7 The latter two studies used polyclonal antisera reactive with clinically irrelevant targets and are in contrast to our results, where there was a clear dose-dependent enhancement of granulocyte ADCC by IFN--, that encompassed both low and high MoAb concentrations. Although these studies reported enhancement by leukocyte IFN-a2' or recombinant IFN-cx,~' we and othersz6 found very little stimulation of granulocyte ADCC by this IFN species. The finding that both IFN species could enhance granulocytes ADCC with antisera containing many classes of antibodies-yet only IFN-7 was active in Lym-1 ADCC-suggested the possibility that the change induced in granulocytes was specific for Lym-1. CD64 binds avidly to murine IgG2a MoAbsZ8 such as Lym-1, and we have shown that IFN--, specifically induced granulocyte CD64. Although IFN--, has many effects on graunl~cytes,'~ the previous discussion suggests that one of the integral components of IFN-7 augmentation of Lym-1 ADCC is CD64 induction. In a different system, it has been suggested that CD64 played a major and, possibly, a limiting role in granulocyte ADCC that was augmented by IFN--,." CD64 induction or upregulation on granulocytes may be an expedient method to monitor a patient's response to IFN-7. This information could provide a rational guideline for designing therapy schedules combining MoAbs that bind to 0 6 4 with IFN-y or cytokines that increase CD64 expression. Further studies are underway to characterize the interaction between Lym-1 and CD64.
IFN--, can upregulate or induce a variety of tumor cell antigens, including class I1 molecules.ls Improved anti-class I1 MoAb localization in a murine breast cancer xenograft model due to induction of class I1 molecules after 4 days of IFN--, treatment has been rep~rted.~' Although this was not seen here, it is possible that IFN--, could upregulate Lym-1 antigen expression on fresh tumor targets or by more prolonged exposure to tumor cell lines in vitro. Studies to examine these possibilities are in progress. IFN--, has been reported to reduce the sensitivity of human tumor targets to lymphokine-activated and natural killer cell lysis.3o We did not observe this phenomenon in PBMC or granulocytemediated Lym-1 ADCC. The potential for exploiting granulocytes as antitumor effectors has been re-examined recently, particularly with the availability of recombinant cytokines. There are only a few reports suggesting that granulocytes by themselves are able to kill or inhibit the growth of tumor cell^.^'*^^ In agreement with others," we found no native tumor lytic ability in either unstimulated or IFN-7-treated granulocytes. One potential problem with granulocytes is whether they can traffic to sites containing antibody-coated tumor cells. Increasing the number and activity of granulocytes by an agent such as granulocyte-macrophage colony-stimulating factor (GM-CSF) may be one way to overcome this problem, and a recent report showed a potential additional benefit: GM-CSF was able to enhance granulocyte ADCC mediated by an IgG3 anti-melanoma MoAb, 3F8.33 Interestingly, and underscoring the need to examine each MoAbcytokine-effector cell combination separately, was the finding that GM-CSF stimulation of granulocyte-mediated 3F8 ADCC was inhibitable by anti-CD16 (type 111 IgG FcR) antibodies.
Lym-1 can interact with human complement to elicit complement-dependent cytotoxicity (CDC) (Vaickus et ovarian cancer after Corynebacterium parvum immunothe rap^,'^ murine mammary adenocarcinoma after intraperitoneal C parvum injection."; virus-induced sarcomas in dogs38; syngeneic rat tumors39; human ovarian cancer after intraperitoneal Cparvum injection4'; and gastric adenocarcinoma in ascites after intraperitoneal injection of OK-432, a streptococcal bacteria d e r i~a t i v e .~' Whether cytokineaugmented granulocytes can localize to tumors in response to a MoAb is an unanswered but important question. Assuming that granulocytes can specifically localize within tumors and mediate ADCC with Lym-1, another consideration is whether "innocent bystander" cells or tissues will be damaged. In the few in vitro studies that have examined this possibility, tumor antigen-negative cells were not damaged by a contiguous granulocyte antitumor ADCC.2'.42 Clinical trials support the feasibility of using IFN--y in combination with MoAbs like Lym-1, despite the fact that information from patients with B-cell tumors is limited. In three separate Phase I studies, IFN-y, given as a single agent to patients with refractory malignancies, caused only mild and reversible toxicities. Two patients with B-cell malignancies (CLL and nomHodgkin's lymphoma) had response^.^'-^^ Of importance to our findings, the majority of patients experienced some degree of neutropenia, which was rapidly reversible in all. Other leukocyte subsets were unaffected. The only clinical study to combine a therapeutic MoAb and INF-y showed that 17-1A (IgG2a, non-complement fixing) was able to mediate ADCC by PBMC and that the reaction was enhanced by IFN-y in vitro and after in vivo administration to patients with colorectal carcinoma.23 Interestingly, low doses of IFN-y augmented ADCC by peripheral blood monocytes more so than higher doses. The lower doses were not accompanied by neutropenia or other hematologic toxicity, yet treated patient's cells displayed augmented ADCC in vitro. These in vitro findings are similar to ours, since augmentation of granulocyte-mediated ADCC was evident at low IFN-y concentrations (10 to 100 U/mL). Unfortunately, 17-1A was not consistently demonstrated at tumor sites, and there were no clinical responses. No results of granulocyte-mediated 17-1A ADCC were reported.
To our knowledge, this study is the first to show that recombinant IFN-y enhanced granulocyte ADCC that was mediated by a MoAb capable of being given to patients. Since there is a paucity of information on ADCC against human lymphoma targets, these studies also provide a model system to explore the potential of exploiting this antitumor mechanism in combination with therapeutic anti-lymphoma MoAbs. For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From
